The Paracetamol AfteR Traumatic Brain InjurY Study

NCT ID: NCT01231139

Last Updated: 2014-10-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This primary aim is to investigate the effect of paracetamol in reducing body temperature in patients who have sustained traumatic brain injury. This study is also investigating the safety of paracetamol in this patient population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Traumatic head injury is a bruising of areas of the brain that occurs commonly as a result of a fall or a motor vehicle accident. Unfortunately, this is a common global occurrence and it occurs both in developing and developed countries. It causes death in nearly 1 in 3 of those who are most severely affected and a large proportion of those that survive have long-term physical or mental disability. Hence, traumatic head injury is a major global problem.

At present there are very few therapies that are known to be effective after a traumatic head injury. In particular the investigators are uncertain about whether modifying body temperature has any effect (good or bad) on the outcomes of patients. Although, this is practiced by some intensive care units around the world.

The investigators have searched extensively to look for any evidence that altering body temperature after traumatic head injury improves the outcome of patients (by reducing the amount of death or disability) and were unable to find any evidence at all. Some preliminary research in both animal experiments and clinical studies suggest that a raised temperature after forms of brain injury may in fact be harmful.

Therefore, at present the investigators believe that we do not really know what effect changing body temperature after head injury has on the outcome of patients.

The investigators are proposing to conduct a clinical study of patients who have had a severe head injury. The patients will be randomly allocated to 2 groups who will get either regular Paracetamol (dissolved in fluid) or a bottle of fluid without any Paracetamol. The 2 treatments will look identical and neither the patients nor the health care workers will know what treatment they are getting. Doing the study in this way will allow us to work out whether giving Paracetamol reduces the temperature of the body and whether there are any side effects that occur. If the study shows that Paracetamol can reduce body temperature safely in this setting then the investigators will work towards doing a larger study of treatments that reduce body temperature. The purpose of this larger study would be to see if the investigators can, not only reduce body temperature but also reduce amount of disability (physical and mental) as well as the death rate in traumatically brain injured patients.

In the proposed study the investigators will be using a higher dose of Paracetamol that is usually prescribed. Other research has shown that the dose that the investigators are proposing to use is safe and also that smaller doses in fact do not reduce body temperature.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paracetamol

Paracetamol dissolved in 0.9% Sodium Chloride

Group Type EXPERIMENTAL

Paracetamol

Intervention Type DRUG

Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).

0.9% Sodium Chloride

0.9% Sodium Chloride

Group Type PLACEBO_COMPARATOR

0.9% Sodium Chloride Schedule:

Intervention Type DRUG

Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paracetamol

Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).

Intervention Type DRUG

0.9% Sodium Chloride Schedule:

Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Perfalgan Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Suspected paracetamol overdose or allergy to paracetamol
* Confirmed or suspected pregnancy
* Use of pharmacological or physical intervention that reduces body temperature in the 6-hour period prior to randomisation.
* Clinician decision to institute any pharmacological or physical intervention that modifies body temperature
* Body temperature at time of recruitment less that 36°C or greater than 38.9°C
* History of chronic liver disease or chronic alcohol abuse
* Suspected malnutrition: BMI \< 18 kg/m2 or weight \< 60 kg
* BMI \> 35 kg/m2
* Renal failure with serum creatinine \> 200
* Haemodynamic instability defined as systolic blood pressure \< 90 mmhg or requirement for noradrenaline or adrenaline exceeding 20mcg/minute
* Use of hepatic enzyme inducers, except for phenytoin
* Minor head injury: either normal CT head or not expected to be in intensive care for 72 hours
* GCS = 3 with fixed dilated pupils
* Moribund patient expected to die within 24 hours
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The George Institute

OTHER

Sponsor Role collaborator

The University of New South Wales

OTHER

Sponsor Role collaborator

Royal Brisbane and Women's Hospital

OTHER_GOV

Sponsor Role collaborator

Dr. M.K. Saxena

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. M.K. Saxena

Intensive Care Physician

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manoj Saxena

Role: PRINCIPAL_INVESTIGATOR

South East Sydney Illawarra Area Health Service

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St George Hospital

Sydney, New South Wales, Australia

Site Status

Royal Brisbane and Women's Hospital

Brisbane, Queensland, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PARITY

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hypothermia in Children After Trauma
NCT00222742 TERMINATED PHASE3
Female Concussion Head Cooling
NCT07303933 NOT_YET_RECRUITING NA